An announcement from Aurinia Pharmaceuticals ( (AUPH) ) is now available.
Aurinia Pharmaceuticals reported significant financial growth in Q3 2024, with net product revenue up by 36% year-over-year, driven by increased market penetration of LUPKYNIS. The company is undergoing strategic restructuring to focus on continued LUPKYNIS growth and AUR200 development, expecting annualized savings of over $40 million post-restructuring. With strong cash flow and revenue guidance between $210-$220 million for 2024, Aurinia aims to enhance operational efficiency and accelerate key pipeline products.
See more insights into AUPH stock on TipRanks’ Stock Analysis page.
Trending Articles
- Icahn to Boost Stake in CVR Energy to 81% by Cutting IEP’s Dividend
- Amazon Considers Additional Multi-Billion Dollar Investment in Anthropic
- Will Palantir Stock Crash by 50%? Here’s What Jefferies Expects
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
%20Slips%20after%20Chip%20Tests%20Fail%20Broadcom%E2%80%99s%20Inspection%20%7C%20Nasdaq&_biz_n=1&rnd=816976&cdn_o=a&_biz_z=1743695065741)
